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The objective of the present study was to determine the acute effect of hemodialysis on endothelial venous function and oxidative
stress. We studied 9 patients with end-stage renal disease (ESRD), 36.8 ± 3.0 years old, arterial pressure 133.8 ± 6.8/80.0 ± 5.0
mmHg, time on dialysis 55.0 ± 16.6 months, immediately before and after a hemodialysis session, and 10 healthy controls
matched for age and gender. Endothelial function was assessed by the dorsal hand vein technique using graded local infusion
of acetylcholine (endothelium-dependent venodilation, EDV) and sodium nitroprusside (endothelium-independent venodilation).
Oxidative stress was evaluated by measuring protein oxidative damage (carbonyls) and antioxidant defense (total radical
trapping antioxidant potential - TRAP) in blood samples. All patients were receiving recombinant human erythropoietin for at
least 3 months and were not taking nitrates or α-receptor antagonists. EDV was significantly lower in ESRD patients before
hemodialysis (65.6 ± 10.5) vs controls (109.6 ± 10.8; P = 0.010) and after hemodialysis (106.6 ± 15.7; P = 0.045). Endothelium-
independent venodilation was similar in all comparisons performed. The hemodialysis session significantly decreased TRAP
(402.0 ± 53.5 vs 157.1 ± 28.3 U Trolox/µL plasma; P = 0.001). There was no difference in protein damage comparing ESRD
patients before and after hemodialysis. The magnitude of change in the EDV was correlated negatively with the magnitude of
change in TRAP (r = -0.70; P = 0.037). These results suggest that a hemodialysis session improves endothelial venous function,
in association with an antioxidant effect.
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Introduction
Patients with end-stage renal disease (ESRD) experi-
ence excess morbidity and mortality due to cardiovascular
disease (CVD). These patients usually have several clas-
sic CVD risk factors, but this does not fully explain the
excessive CVD mortality (1). Among the emerging CVD
risk factors, endothelial dysfunction and oxidative stress
are currently emphasized, not only because they could
explain the high incidence of CVD events in the ESRD
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population compared with the general population (2), but
also because they may be new targets for therapeutic
interventions.
Impaired endothelium-dependent vasodilation is ex-
tensively described in patients with ESRD undergoing
renal replacement therapy by hemodialysis (3-5), a defect
that may predispose them to accelerated atherosclerosis,
as described for non-uremic patients with decreased en-
dothelium-mediated vasodilation and coronary artery dis-
ease (6). Renal replacement therapy by kidney transplan-
tation improves endothelial function (7), but reports of
results obtained after hemodialysis are contradictory, some
reporting improvement (3,8,9), others not (10,11), and yet
another one showing increased endothelial dysfunction
after a single session of hemodialysis (12).
Patients with ESRD have increased levels of oxidative
stress markers and impaired endothelial cell function (13).
Both reduced antioxidant systems and increased pro-oxi-
dant activity generate the increased oxidative stress ob-
served in ESRD patients (1). Even a single hemodialysis
session can increase plasma levels of oxidized LDL (12)
and decrease total antioxidant capacity (14). Thus, hemo-
dialysis would indeed induce oxidative stress and impair
the bioactivity of nitric oxide (NO). However, several stud-
ies have demonstrated that endogenous inhibitors of NO
synthase accumulate in ESRD (8,15) and are cleared by
dialysis (8). Therefore, hemodialysis should be beneficial
to endothelial function in view of its ability to clear dialysa-
ble endothelial toxins, but its known effect of causing high
levels of oxidative stress could interfere with this effect.
All but one study cited above evaluated arterial endo-
thelial function. The capacitance vessels are important in
circulatory homeostasis. Indeed, the endotheliums of ar-
teries and veins have different biological activities prob-
ably due to marked regional and segmental heterogeneity
in vascular endothelial function (16). During hemodialysis,
a large amount of fluid is removed from the body, thus the
capacitance venous system would be expected to be
influenced more than the arterial system. The aim of the
present study was to determine endothelium-dependent
and -independent venous function in patients with ESRD
using the dorsal hand vein technique and by measuring
oxidative stress before and after a single hemodialysis
session.
Material and Methods
This study was performed on 9 patients (6 women and
3 men) with established ESRD (estimated glomerular filtra-
tion rate <15 mL/min), who had been maintained on renal
replacement therapy with hemodialysis for at least three
months at the Nephrology Unit of Hospital de Clínicas de
Porto Alegre. Hemodialysis was performed three times a
week (~4 h/session). All patients were receiving recombi-
nant human erythropoietin (3000-6000 U/week) for at least
3 months. Four patients were taking angiotensin-convert-
ing enzyme (ACE) inhibitors, two patients were taking ACE
inhibitors plus diuretics, two patients were taking ACE
inhibitors plus calcium channel blockers, and one patient
was taking an ACE inhibitor plus an antiplatelet agent. The
patients were not given nitrates or α-receptor antagonists.
All medications were discontinued 12 h before the evalua-
tion. During the period of the study, all patients continued
the usual dialysis prescribed using Fresenius Medical
Care 4008 B dialysis machines with polysulfone mem-
branes (Fresenius Medical Care, GE). All patients were
dialyzed against bicarbonate. Ten age- and sex-matched
healthy control subjects (6 women, 4 men) not using any
medication were also recruited. The study was previously
approved by the local research Ethics Committee (process
02-413/2002) and all subjects gave a written informed
consent.
Exclusion criteria included diabetes, age >60 years,
smoking, obesity (body mass index >30 kg/m2) and pa-
tients who had hypotensive episodes during hemodialysis
(more than 20 mmHg mean arterial pressure reduction).
No patient had symptomatic coronary artery disease or
cerebrovascular disease. The etiology of ESRD was as
follows: systemic arterial hypertension (N = 2), polycystic
kidney disease (N = 2), reflux nephropathy (N = 2), focal
segmental glomerulosclerosis (N = 1), Henoch-Shoenlein
purpura (N = 1), and unknown (N = 1). All subjects avoided
caffeine and alcohol-containing drinks on the day of the
study and were fasted for at least 4 h before each evalua-
tion. They were given sodium heparin as a bolus dose of
5000 U at the beginning of dialysis, followed by 1000 U/h.
Dorsal hand vein technique
Venous endothelial function was assessed in all pa-
tients and controls with the dorsal hand vein technique
immediately before and after hemodialysis with the same
hand vein on the non-fistula arm or the non-dominant arm
in controls. The dorsal hand vein technique used was
described by Aellig (17), and has been used by our group
(18). Briefly, a 23-gauge butterfly needle was inserted into
a suitable vein on the back of the hand with the arm
positioned at an upward angle of 30 degrees and a con-
tinuous infusion of 0.9% saline (0.3 mL/min) was started. A
tripod holding a linear variable differential transformer
(LVDT; Shaevitz Engineering, Pennsauken, NJ, USA) was
mounted on the hand with the central aperture of the LVDT
that contained a movable metallic core at a distance of 10
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mm downstream from the tip of the needle. The signal
output of the LVDT, which is linearly proportional to the
vertical movement of the core, provided a measurement of
the vein diameter. Readings were taken at a congestive
pressure of 40 mmHg by inflating a blood pressure cuff
placed on the upper portion of the arm being studied.
Results are reported as normalized dose-response curves
in which the diameter of the vein during saline infusion with
the cuff inflated was taken to be 100% relaxation.
The vein was preconstricted by infusing increasing
doses of the α1-adrenergic selective agonist phenyleph-
rine (25 to 8333.3 ng/min) until the dose that produced
approximately 70% constriction of the vein was identified
(ED70). This degree of preconstriction was taken to be 0%
venodilation. The endothelium-dependent venodilation was
assessed with incremental infusions of acetylcholine (ACh;
3.6, 36, 360, 720, 1800 ng/min), and endothelium-inde-
pendent venodilation with sodium nitroprusside (SNP; 495.3
and 990.6 ng/min) was calculated to be the percent of the
range between 100 and 0% vasodilation. Drugs were
infused with a Harvard infusion pump (Harvard Apparatus
Inc., South Natick, MA, USA). Blood pressure and heart
rate were monitored in the right leg with a sphygmoma-
nometer. Ambient temperature was maintained between
21 and 24°C.
Oxidative stress
Oxidative stress was measured in the ESRD patients
and evaluated by measuring oxidative damage (protein
oxidation) and antioxidant defense (total radical trapping
antioxidant potential - TRAP). Blood samples were ob-
tained pre- and post-hemodialysis (pre-HD and post-HD),
centrifuged for 10 min at 1000 g (Sorval RC 5b-rotor SM
24, Du Pont Instruments, Norwalk, CT, USA), and plasma
was separated.
Plasma was used to determine protein oxidation by
means of carbonyl group measurements. It was incubated
with 2.4 dinitrophenylhydrazine (10 mM) in a 0.8 mL 2.5 M
HCl for 1 h at ambient temperature in the dark. Samples
were vortexed every 15 min. Then, 1 mL 20% TCA (w/v)
was added to a 0.2-mL sample, left in ice for 10 min and
centrifuged for 5 min at 1000 g, to collect protein precipi-
tates. Another wash was performed with 0.8 mL cold 10%
TCA. The pellet was washed three times with ethanol:ethyl
acetate (1:1) (v/v). The final precipitates were dissolved in
6 M guanidine hydrochloride, left for 10 min at 37°C, and
absorbance was read at 360 nm (19). The results are
reported as nmol/mg protein.
TRAP or antioxidant capacity, was measured by lumi-
nescence using 2,2'-azo-bis (2-amidinopropane), a source
of alkyl peroxyl free radicals, and luminol. A calibration
curve was obtained using 0.2 to 1 µM Trolox (6-hydroxy-
2,5,7,8-tetramethylchroman-2-carboxylic acid). The addi-
tion of plasma samples instead of Trolox elicits an induc-
tion time related to the initial amount of sample added (20).
Luminescence was measured with a scintillation counter
in the out-of-coincidence mode and the results are re-
ported as mM Trolox/mg protein.
Other biochemical measurements
Blood samples were obtained before and after dialysis
for analysis of hematocrit, total cholesterol, triglycerides,
and plasma glucose. Total cholesterol, triglycerides and
plasma glucose were determined by automated enzymatic
commercial kits (Roche, Mannheim, Germany).
Statistical analysis
Analyses were performed using SPSS® Base 13.0
(SPSS Inc., Chicago, IL, USA). Results are reported as
means ± SEM. Data for all patients were included in the
calculations for all Tables and Figures. Variables that did
not have a Gaussian distribution (Kolmogorov-Smirnov
test) were log-transformed before analyses (log10). Differ-
ences were analyzed using the Student paired or unpaired
t-test as appropriate. The dose-percentage venodilation
maximum response curves in each ACh dose were ana-
lyzed by two-way repeated measures ANOVA followed by
the post hoc Bonferroni test. The magnitude of change (∆)
in the endothelium-dependent venodilation, TRAP and
carbonyls was calculated as the difference between pre-
and post-HD. The association between endothelial venous
function and oxidative stress was calculated using Pear-
son’s correlation. The differences were considered to be
statistically significant when P < 0.05.
Results
Table 1 shows the clinical and laboratory characteris-
tics of the patients and controls studied. No differences
were observed between the control group and patients
with ESRD concerning age and body mass index. There
were significant differences in hematocrit between pre-HD
and controls (P < 0.001), pre-HD vs post-HD (P = 0.012),
and in body weight from pre-HD to post-HD evaluation (P
< 0.001). There were no differences between controls vs
pre-HD and between pre-HD vs post-HD in terms of total
cholesterol, triglycerides, plasma glucose, systolic arterial
pressure, diastolic arterial pressure, and mean arterial
pressure. The mean time since the beginning of hemodi-
alysis was 55.0 ± 16.6 months.
Endothelial venous function data are shown in Table 2.
Maximum venodilation by ACh was significantly improved
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after a single hemodialysis session (P = 0.045).
Endothelium-dependent venodilation was sig-
nificantly lower in pre-HD patients compared
with controls (P = 0.010). Dilation in response
to SNP (endothelium-independent venodilation)
was similar pre- and post-HD, or when com-
pared to controls.
Figure 1 presents the ACh vs venodilation
dose-response curve. The doses of pre- and
post-HD response curves were similar and the
magnitude of the response was increased by
hemodialysis (P < 0.001).
The dose of phenylephrine to reach ED70
and doses of ACh and SNP needed to reach
maximum venodilation were not different be-
tween controls and pre-HD patients or pre-HD
vs post-HD measurements (Table 2). There
were no significant differences in the diameter
of baseline venodilation between controls (1.0
± 0.1 mm) and pre-HD patients (0.9 ± 0.1 mm)
and in pre-HD patients (0.9 ± 0.1 mm) vs post-
HD patients (1.1 ± 0.2 mm).
No protein oxidative damage was observed
when pre-HD (15.8 ± 0.6 nmol/mg protein) vs
post-HD (16.6 ± 0.6 nmol/mg protein) were
compared. However, there was a significant
reduction of TRAP when pre-HD (402.0 ± 53.5
U Trolox/µL plasma) vs post-HD (157.1 ± 28.3
U Trolox/µL plasma) were compared.
A negative correlation was detected be-
tween ∆ of the endothelium-dependent
venodilation and ∆ of TRAP (Figure 2) when
pre-HD and post-HD were compared. How-
ever, no correlation was demonstrable between
∆ of endothelium-dependent venodilation and
∆ of carbonyls.
Figure 1. Endothelial venous function of patients with end-stage
renal disease before and after hemodialysis. The average maxi-
mal percentage venodilation is plotted against acetylcholine
dose. Two-way repeated measures ANOVA was used for all
comparisons between before (pre-HD; N = 9) and after hemodi-
alysis (post-HD; N = 9). *P < 0.05 vs pre-HD (post hoc Bonferroni
test).
Table 2. Endothelial venous function of patients with end-stage renal disease
before (pre-HD) and after hemodialysis (post-HD) and controls.
Response Control Pre-HD Post-HD
(N = 10) (N = 9) (N = 9)
Venoconstriction (%, phenyl) 77.0±2.9 78.8±3.9 78.1±4.2
Emax (%, acetylcholine) 109.6±10.8 65.6±10.5* 106.6±15.7+
Emax (%, SNP) 147.7±13.1 150.3±13.7 157.2±16.3
Drug infusion concentrations
ED70 (ng/min, phenyl) 38.9±10.1 61.1±20.8 65.3±21.6
Emax (ng/min, acetylcholine) 964.0±222.4 892.0±290.2 865.1±277.9
Emax (ng/min, SNP) 594.4±66.0 550.3±55.0 605.4±72.8
Data are reported as means ± SEM for all subjects. Phenyl = phenylephrine;
SNP = sodium nitroprusside; Emax = maximum effect; ED70 = dose that
produced approximately 70% constriction of the vein. Drug infusion concen-
trations are reported before log10 transformation.
*P < 0.05 vs controls (Student unpaired t-test); +P < 0.05 vs pre-HD (Student
paired t-test).
Table 1. Clinical and laboratory characteristics of patients with end-stage
renal disease before (pre-HD) and after hemodialysis (post-HD) and controls.
Parameter Control Pre-HD Post-HD
(N = 10) (N = 9) (N = 9)
Hematocrit (%) 41.8 ± 1.3 31.6 ± 1.6* 35.5 ± 1.9+
Total cholesterol (mg/dL) 181.9 ± 8.9 160.3 ± 12.8 161.6 ± 13.0
Triglycerides (mg/dL) 66.8 ± 5.9 78.1 ± 7.5 78.8 ± 5.6
Plasma glucose (mg/dL) 87.6 ± 1.8 90.5 ± 1.3 92.4 ± 2.4
Body weight (kg) 66.1 ± 3.4 60.2 ± 4.0 57.6 ± 3.9+
Systolic arterial pressure (mmHg) 118.0 ± 3.4 133.8 ± 6.8 127.5 ± 4.1
Diastolic arterial pressure (mmHg) 74.3 ± 2.6 80.0 ± 5.0 80.0 ± 3.3
Mean arterial pressure (mmHg) 88.9 ± 2.8 97.9 ± 5.0 95.8 ± 3.0
Data are reported as means ± SEM for all subjects.
*P < 0.05 vs controls (Student unpaired t-test); +P < 0.05 vs pre-HD (Student
paired t-test).
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Discussion
The data presented here show that endothelium-de-
pendent venodilation was impaired in patients with ESRD
and that a single hemodialysis session can improve it
significantly. Hemodialysis also reduced plasma TRAP
and unmodified protein damage. Moreover, endothelium-
dependent venodilation was correlated negatively with
plasma TRAP.
The results of several studies (3-5) suggest that endo-
thelial dysfunction is present in patients with ESRD submit-
ted to maintenance hemodialysis. However, only the pres-
ent study and the one reported by Hand et al. (3) in 1998
evaluated the endothelial venous function. Our data are in
agreement with theirs in showing the presence of endothe-
lial venous dysfunction - that is improved after a single
hemodialysis session - and no impairment of endothelium-
independent vasodilation. The improvement of endothelial
function has already been reported by others in the arterial
bed (8,9) and in the venous bed (3). However, in the
present study, endothelial function was measured immedi-
ately before and immediately after hemodialysis, while in
the study of Hand et al. (3), the pre-dialysis evaluation was
performed >24 h after the previous hemodialysis session
and <16 h before the next one. This is important, because
the improvement of endothelial function persists for only 5
h after hemodialysis (8).
In other studies (8,9), endothelial function was meas-
ured by flow-mediated dilatation of the brachial artery and
forearm plethysmography, whereas we performed the en-
dothelial evaluation using a pharmacological stimulus
(ACh). We measured the vasodilation in the venous vascu-
lar bed, which seems to be advantageous, considering the
close relationship between venous capacitance bed and
hemodialysis-induced changes. Also, arterial wall changes
induced by hypertension and atherosclerosis, both very
common in these patients, could cause unexpected vaso-
dilatory responses not actually representing endothelial
dysfunction.
Our data, however, are different from those of Miyazaki
et al. (12) who suggested that hemodialysis per se impairs
endothelial function. We think that the venous bed is a
more sensitive target of changes, so we could detect the
improvement induced by the hemodialysis session be-
cause the dorsal hand vein is more sensitive to detect this
improvement in this setting compared to flow-mediated
vasodilation during reactive hyperemia using high-resolu-
tion ultrasound Doppler echocardiography. Even though
we excluded patients who presented hypotension during
the hemodialysis session, weight reduction was observed,
because fluid was effectively removed by the procedure.
This fact could be responsible for improved venous com-
pliance and consequently, better endothelium-dependent
venodilation after the hemodialysis session.
Improvement in endothelial venous function could be
explained by other factors not studied by us. Asymmetric
dimethylarginine (ADMA, an endogenous inhibitor of NO
synthase), total plasma homocysteine (which directly dam-
ages the endothelium and may inactivate NO) (8,21) and
ADMA/L-arginine ratio fell significantly after hemodialysis,
but there was no correlation between the plasma concen-
trations of these substances and flow-mediated dilation
(8). However, another study showed that ADMA and sym-
metric dimethylarginine were poorly eliminated during he-
modialysis. This is probably due to a high level of binding
of both molecules to plasma proteins (22). Be that as it
may, the concentrations of both dimethylarginines are
increased in patients with ESRD and may explain at least
in part endothelial dysfunction in this patient population.
Our results also present a reduction of TRAP induced
by hemodialysis, which was not accompanied by protein
oxidative damage. We did not evaluate other markers of
Figure 2. Plot of ∆ TRAP (total radical trapping antioxidant poten-
tial) reduction and ∆ venodilation induced by acetylcholine during
the endothelial venous function determination. The Pearson cor-
relation test was used to test the correlation for all 9 patients.
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oxidative damage and antioxidant defense; therefore, we
could not effectively prove that oxidative stress did not
occur. However, increased endothelium-dependent va-
sodilation and reduced TRAP occurred after hemodialysis
and were correlated negatively. These changes might
mean that antioxidant defenses are effectively related to
endothelial venous function improvement induced by di-
alysis, because patients with major improvement in endo-
thelial function presented the lower TRAP reduction. Oxi-
dative stress was measured through a very sensitive meth-
od that involves chemiluminescence, allowing high preci-
sion determinations with small amounts of sample (23).
One limitation of our study was that we did not measure
systemic inflammatory mediators that could be related to
chronic renal failure itself and also to the hemodialysis
session (24), since changes in these mediators could
partially explain the endothelial function improvement.
Our results are different from those of Miyazaki et al.
(12), who demonstrated that hemodialysis impairs endo-
thelial function via oxidative stress, but their results could
be related to the different plasma markers they used (oxi-
dative damage and TRAP vs oxidized LDL). However,
endothelial dysfunction is not related to LDL oxidation,
suggesting that LDL oxidation might not be a major cause
of vascular endothelial dysfunction in ESRD (25). Consid-
ering the present data, antioxidant treatments could be
useful to improve the endothelial venous function of pa-
tients submitted to hemodialysis. Previous studies showed
that a vitamin E-coated dialyzer may decrease oxidative
stress (12,26), and oral vitamin E can reduce cardiovascu-
lar events in patients on hemodialysis (27). These studies
further support the role of oxidative stress and its treatment
in the development and prevention of cardiovascular com-
plications in these patients.
It is well-known that endothelium-dependent vasodila-
tion is positively correlated with total antioxidative activity,
reduced glutathione (GSH), and lag phase of LDL and
negatively correlated with oxidized GSH (GSSG), GSSG/
GSH and diene conjugates, showing that an impaired
endothelium vasodilation function and oxidative stress are
related to each other in patients with ESRD (13). A recent
study showed that flow-mediated dilation, oxidative stress,
and ADMA levels are associated with ESRD. Additionally,
levels of oxidative stress markers and ADMA independent-
ly determine endothelial function (28).
The present findings allow us to conclude that a single
session of hemodialysis improved endothelial venous func-
tion and that antioxidant potential might be associated with
this improvement in patients with ESRD. The evaluation of
venous and arterial endothelial function in these patients,
before and after a hemodialysis session, can provide bet-
ter understanding of the difference of responses observed
between the different vascular beds. Just as patients with
ESRD present endothelial dysfunction for multifactorial
reasons, changes in endothelial function resulting from a
hemodialysis session must also be attributed to a combi-
nation of factors that have not yet been fully identified.
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